First patient treated with Leqembi® (lecanemab) in Sweden
Why now
Thesis: European Leqembi rollout begins, validating Alzheimer's therapy commercialization
Catalyst to watch: Further EU country launches and reimbursement decisions
Main risk: Slow adoption or payer pushback limits revenue
Why it matters
First Swedish commercial Leqembi treatment signals gradual European rollout of Alzheimer's therapy, relevant to BioArctic and Eisai/Biogen partners.
Details
STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a...
Sources
- prnewswire · 2026-09-22 14:39 UTC